Continuing Education Activity

T-PLL (T Prolymphocytic leukemia) is a mature and aggressive T-cell leukemias characterized by the proliferation of small to medium-sized prolymphocytes that show mature or post-thymic T cell phenotype. T-PLL involves peripheral blood (PB), bone marrow (BM), lymph nodes, liver, spleen, and skin. The name "prolymphocyte" is inaccurate, as the tumor cells in this disease are of post-thymic T cell in origin. T-PLL increases in ataxia-telangiectasia (ATM) patients. Whole-genome sequencing and whole-exome sequencing have demonstrated mutations in the following genes: IL2RG, JAK1, JAK3, STAT5B, EZH2, FBXW10, and CHEK2. This activity reviews the evaluation of T cell prolymphocytic leukemia and identifies the role of the interprofessional team in managing this condition.

Objectives:

• Review the evaluation of a patient with T cell prolymphocytic leukemia.
• Describe the presentation of T cell prolymphocytic leukemia.
• Outline the treatment of T cell prolymphocytic leukemia.
• Summarize the evaluation of T cell prolymphocytic leukemia and identify the role of the interprofessional team in managing this condition.

Introduction

T-PLL (T Prolymphocytic leukemia) is a rare, aggressive T-cell leukemias characterized by the proliferation of small to medium-sized prolymphocytes that show a mature T cell phenotype. The average age of patients with T-PLL is 65 (the age range is 30 to 94 years). Generally, it comprises 2% of mature lymphocyte leukemias. It has a rapid doubling time and a doleful course with a median survival of 1 year. Between 20 and 30% of patients initially present with inactive disease, but they always progress to an active format within two years. T-PLL is often widespread at diagnosis and involves the peripheral blood (PB), bone marrow (BM), lymph nodes, liver, spleen, and skin. The name "prolymphocyte" is not accurate, as the tumor cells in this disease are of post-thymic T cell in origin.[1] 

After confirming the diagnosis, the next clinical objective is to determine the disease's activity as the only active disease is treated. Chemotherapy's efficacy is poor. Agents that can offer a response cannot provide long-term control. Bone marrow transplantation (BMT) can provide a long-term response but typically only in patients with a good complete response (CR) to induction chemotherapy, those in good condition/health, and young enough to allow a BMT protocol. 

Etiology

T-PLL has no known transformations, nor does it have any known environmental risk factors. Whole-genome sequencing and whole-exome sequencing have demonstrated mutations in the following genes: IL2RG, JAK1, JAK3, STAT5B, EZH2, FBXW10, and CHEK2.[2]  Patients with ataxia-telangiectasia mutation (ATM) have an increased incidence of T-PLL. ATM is an autosomal recessive disorder characterized by progressive neurological dysfunction (e.g., ataxia), immunodeficiency, impaired organ development, and oculocutaneous telangiectasia. Mutations of the ATM gene on 11q23 occur in 80 to 90% of the T-PLL population. There is a rare association of T-PLL with breast malignancy and renal transplant.[3][4]

Epidemiology

T-PLL is a rare T cell leukemia. The disease accounts for approximately 2% of cases of mature lymphocytic leukemia in adults. The pathology is common in elderly patients (older than 65 yrs) with an age range of 30 to 94 years. There is a slight male predominance with a male to female ratio of 1.33.

Pathophysiology

In healthy T cells, TCL1 is expressed in CD4-/CD8- cells but not in cells at later stages of differentiation. The TCL1 gene rearrangements on chromosome 14 are the most common genomic alterations; they increase the expression of the gene. The overexpression of the TCL1 gene and its protein in humans has been involved in the development of T-PLL by serving as a co-activator of the cell survival kinase AKT.

The most frequent chromosome 14 alterations involve inv(14)(q11;q32) in 80% of patients and involve the TCL1a and 1b, t(14;14)(q11;q32) in 10% of cases; they also involve TCL1a/1b and t(X;14)(q28;q11) which involves MTCP1 (Mature T-Cell Proliferation 1). Fluorescence in situ hybridization (FISH) is often used to diagnose rearrangements of the T-cell receptor locus (TCL1). 

TCL1 and MTCP1 (rare) alterations play a crucial role in the pathogenesis of T-PLL by enhancing cell proliferation and survival. TCL1 and MTCP1 alterations lead to activation of protein kinase B (Akt), impairment of protein kinase C (PKC) theta, and extracellular signal-regulated kinase (ERK) pathways. Their alterations are necessary initiating events but are not sufficient to drive leukemogenesis in T-PLL.[1] It is thought that the accumulation of various mutations, with the resultant complex karyotype, becomes the driving force in the development of T-PLL. Complex karyotypes are very common in T-PLL, involving 70 to 80% of patients with abnormalities of chromosomes 6, 8, 2p, and 17p.[5] Abnormalities of chromosome 8 include trisomy 8 and isochromosome 8, leading to the overexpression of MYC. TP53 rarely occurs in T-PLL. JAK-STAT pathway genes IL2RG, JAK1, JAK3, and STAT5B also occur. There is an additional deletion of chromosome 11q22.3, the anomaly correlated with Ataxia-Telangiectasia. Patients frequently have mutations in genes coding for histone modifications, as exemplified by KMT2C, KMT2D, KMT 5A, and EZH2. 

History and Physical

Diagnosis of T-PLL is usually established based on a combination of clinical presentation, imaging, morphology, genetics, and immunophenotype.[6][7][8][9] Common symptoms of T-PLL include night sweats, weight loss, fatigue, and weakness. Leucocytosis (high count greater than 100 k), atypical lymphocytosis, anemia, and thrombocytopenia are common findings on the Complete blood count and peripheral blood smear. The bone marrow is positive in 100% of patients with cytopenias. A bone marrow biopsy is not necessary for the diagnosis. Significant clinical findings also include hepatosplenomegaly, generalized lymphadenopathy, skin/mucosal lesions, and effusions (primarily pleural; secondarily peritoneal).

Evaluation

Laboratory studies useful in assessing T-PLL patients include a CBC with smear evaluation, routine chemistries with liver and renal function and electrolytes, alkaline phosphatase, and lactate dehydrogenase (LDH). Imaging studies to assess the extent of the disease include chest X-ray, computed tomography (CT) of the chest, abdomen, and pelvis.[6] PET scans are not generally advocated. 

Peripheral blood smear assessment helps assess T-PLL morphology. There are three reported morphologic variants observed in T-PLL. The typical variant is common and accounts for up to 75% of cases. In this variant, cells are usually small to medium in size. It is also lymphoid cells with non-granular basophilic cytoplasm; round, oval, or markedly irregular nuclei. It shows clumped chromatin. It usually has visible, punched-out nucleoli. The “small cell variant” (20%) shows cells that are relatively small in size; cells show condensed chromatin and small nucleolus (oft invisible to light microscopy). The “cerebriform (Sezary cell-like) variant” (5%) shows cells with an irregular nuclear outline. There are no differences, clinically, between these variants. T-PLL cannot be diagnosed definitively based on cell morphology alone.[10] Irrespective of the nuclear features, a common morphological feature is cytoplasmic protrusions or blebs.

Bone marrow aspirate/bone marrow biopsy in T-PLL cases usually shows diffuse interstitial infiltrates. Tissue biopsy is sometimes necessary for assessing patients with unusual presentation. Spleen biopsy shows red pulp infiltration. Skin biopsy shows perivascular, peri-adnexal, or more diffuse dermal infiltrate without epidermotropism.[6][1]

Flow cytometry is a useful tool often necessary to confirm T-PLL diagnosis. Cells are negative for TdT, CD1a, CD16, CD30, and CD20. The cells are positive for CD3 (weak), CD2, CD5, CD7, and CD52. There is some variation amongst CD4 and CD8 positivity; the majority (60%) of cases are CD4+ and CD8-.  Twenty-five percent are positive for both CD4 and CD8, and 15% are positive for CD8 but CD4-. 

Clonal T-cell receptor gene testing is obligatory for the initial evaluation. TCL1 protein testing using flow cytometry or immunohistochemistry is thought to be more sensitive than cytogenetics and is considered a diagnostic objective. In extremely rare cases where patients have no TCL1A, TCL1B, or MTCP1 rearrangement/overexpression, the diagnosis of TCL1- T-PLL is made. Genetic studies are usually necessary to confirm the T-PLL diagnosis. TCR gene rearrangement is positive for clonal rearrangement. Complex chromosomal abnormalities are very common. Rearrangements involving TCL1 is specific for T-PLL, these include: inv(14) (80%), t(14;14)(q11;q32) (10%) and t(X;14)(q28;q11). Other genetic co-abnormalities can include defects in chromosome 8, del(12p13),  chromosome 6 (33%)  chromosome 17 (26%) and (rarely) deletion of TP53 gene (17p13).[6][7]

Diagnostic Criteria For T-PLL as composed by the TPLL International Study Group.[10] Diagnose T-PLL with all three major criteria OR the first two major criteria (#1,#2) and one minor criterion.

Major Criteria

1. > 5 x 10(9) /L cells with TPLL phenotype in the peripheral blood or bone marrow
2. T-cell clonality [determined by TRB/TRG (T-cell receptor beta/gamma) or flow cytometry]
3. Abnormalities of 14q32 or Xq28 or expression of TCL 1a/b OR MTCP1

Minor Criteria

1. Chromosome 11 abnormalities (11q22.3), as in ATM
2. Chromosome 8 abnormalities [idic (8)(p11), t(8;8), trisomy 8]
3. Chromosome 5,12,13, and 22 abnormalities or a complex karyotype
4. Involvement of a TPLL specific site (e.g., splenomegaly, effusions)

Treatment / Management

Asymptomatic patients should undergo observation, a "watch-and-wait" attitude. They should be followed monthly by physical examinations and laboratory tests, including complete blood counts. The appearance of symptoms warrants treatment. Recall that the asymptomatic period is a transitory respite. Anticipation and preparation are in order; patients will progress.  

The treatment of T-PLL has become relatively restricted, and patients, where applicable, should be considered for clinical studies. The older armamentarium of splenectomy, splenic radiation, leukapheresis, and CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) have been shown to be ineffective in the treatment of T-PLL. Nucleoside agents such as fludarabine, cladribine, and Pentostatin have only a modicum of effect. 

Alemtuzumab (AKA CAMPATH-1-H) remains the mainstay of therapy for the treatment-naive patient as well as those with refractory or relapsed disease.[11][12][13] It carries a response rate (RR) of 90% with a complete response rate (CR) of about 80% in the treatment-naive. The intravenous format for 10 to 12 weeks is favored over the subcutaneous as the drug activity is reportedly lessened in the latter. There are no data to date to support the use of maintenance alemtuzumab. Alemtuzumab is a humanized unconjugated IgG1 monoclonal antibody against CD52, an antigen replete on T-cells. Alemtuzumab binds to CD52 and induces cell death by either complement-dependent cytotoxicity, antibody-dependent cytotoxicity, or apoptotic induction. Unfortunately, even with the best response, relapse follows therapy often well within two years of treatment. For this reason, hematopoietic stem cell transplant (HSCT) is used as a consolidative therapy. 

Allogeneic HSCT (alloHSCT) is favored as consolidation therapy, particularly when started early (within a year of diagnosis) when used in patients who are fit for transplant protocols and for those patients in CR (NOT in partial response [PR] or less). Purportedly autologous and allogeneic HSCT have no significant differences though data for the former are limited. Clinical opinion appears mixed, but alloHSCT, under ideal conditions for consolidation, has produced up to seven years of disease control. 

As stated before, when possible, eligible patients should be screened for entry into clinical trials of newer agents. Recent clinical trials have shown some potential for a BCL-2 (B-cell Lymphoma 2) inhibitor, Venetoclax, in T-PLL.[14] BCL-2 is an anti-apoptotic gene that conveys chemoresistance. Its overexpression prolongs cancer cell survival. The addition of Ruxolitinib is thought to potentiate the action of Venetoclax. It is a JAK1 and JAK2 inhibitor - blocking the ATP-sites of these kinases. Additional studies should be forthcoming. 

Differential Diagnosis

The differential diagnosis of T-PLL includes other lymphoid neoplasms with a leukemic presentation; some relevant entities include [15]:

• B cell prolymphocytic leukemia (B-PLL); B-PLL, compared to T-PLL, has minimal lymphadenopathy and rarely skin involvement. It shows a strong B-cell marker study (CD19, CD20, CD22) with additional positive markers of CD79a and CD5. CD23 is negative. The cytogenetics shows no t(11;14), but there is positivity for 13q del, 11q del, 17p del, or 6q del. The median survival in B-PLL is three years; it is measured in months for T-PLL. Cytologically they bear a single prominent nucleolus. 
• Chronic lymphocytic leukemia/Small lymphocytic lymphoma (CLL/SLL); the cells are variably positive for CD5 and CD23; weakly positive for CD22 and CD79b. They are CD10 negative. The cytogenetic analysis shows 13q del, 11q del, 17p del, or trisomy 12.  
• Mycosis fungoides (MF) / Sezary syndrome (SS); Cells in Sezary syndrome are positive for CD2 and CD3. They are predominantly positive for CD4. They are positive for CD25 and negative for TCL1. They are usually negative for CD7 and CD26. Skin lesions may be found in as many as 20% or so of patients. A skin biopsy may be needed to exclude Sezary syndrome. The rash in SS is felt to be the harbinger of its lymphocytosis. 
• Adult T cell lymphoma/leukemia (ATLL); Chronic HTLV-1 infection is thought to be the etiology of this neoplasm. Here, HTLV-1 PCR/serology is positive; T-PLL cells are negative for this indication. ATLL cells are TCL1 negative. They are positive for CD3, CD4, and CD25. They are CD7 negative; T-PLL cells are CD7 positive. By far, in ATLL, CD4 is more prevalent than CD8. Hypercalcemia is common in ATLL but NOT found in T-PLL. ATLL cells have a unique cytomorphology with "flower cells." These are cells having convoluted nuclei with condensed, homogenous chromatin. 
• T cell large granular lymphocyte leukemia (LGL);  These cells are TCL1 negative though they are positive for CD2, CD3, CD8, CD16, and CD57. They variably express CD7 and rarely CD4. The patients may have mild-to-moderate splenomegaly but rarely lymphadenopathy. Cytopenias are a frequent finding. The cytology reveals large lymphocytes containing azurophilic granules. The median survival is over ten years. 
• Hairy cell leukemia (HCL);  HCL is rare and is noted to be a low-grade mature B-cell cancer. 'Classic' HCL bears B-cell markers of CD19, CD20, and CD22. Markers more specific for this entity include CD11c, CD25, CD103, CD125, and CD200.   An HCL variant exists missing both CD25 and CD123. CD22 and CD79b are variably expressed. However, the variant contains a characteristic BRAF-V600E mutation, a marker not evident in other B-cell maladies. The physical exam is noteworthy for massive splenomegaly, essentially its most prominent feature. Cellular morphology shows "hair"-like cytoplasmic projections. The variant form may manifest nucleoli.   

Prognosis

T-PLL is an aggressive malignancy with a median survival of one to two years. The median overall survival is 21 months. Some patients may present with the indolent variant, which shows a better prognosis. Poor prognostic factors include age above 65, presence of effusion, hepatic or nervous system involvement, bulky lymph nodes, high absolute lymphocytic count, high expression of TCL1 and AKT1, and JAK3 mutation.[1] Having at least five cytogenetic abnormalities was a negative prognostic factor for survival. An elevated LDH or beta-2-microglobulin reportedly portends a poor response to therapy. 

Complications

The administration of treatment requires preparatory measures to prevent problems. For alemtuzumab, preparation includes prophylaxis against tumor lysis syndrome, antimicrobial prophylaxis (Pneumocystis jiroveci and Herpesviridae [HSV, CMV]), and monitoring for CMV reactivation. CNS prophylaxis currently is not advocated as bone marrow transplantation may be a serious consolidative therapy for the T-PLL patient; the lengthy process of human leukocyte antigen (HLA) typing of siblings should be initiated as soon as possible.

Deterrence and Patient Education

Before beginning treatment, patients should receive education about the prognosis and possible adverse side effects of chemotherapeutic regimes and hematopoietic stem cell transplantation.

Pearls and Other Issues

The first objective, post-diagnosis of T-PLL, is to determine the disease activity. A "watch and wait" attitude is appropriate for those few patients with inactive disease. However, this is tempered by the fact that these individuals will progress shortly to active disease. It is, therefore, best to approach all patients in both a preparatory and anticipatory mode. A number of preparations should begin concurrently in anticipation of the rapid progress of T-PLL. Patients should undergo screening for their eligibility in clinical trials. Simultaneously, patients can undergo a CMV status check, and their siblings begin HLA typing, the former regarding alemtuzumab therapy and the latter for allogeneic bone marrow transplant. A bone marrow transplant would become especially important if the patine obtains a CR on Alemtuzumab. These preparations are best done concurrently, NOT sequentially. 

Enhancing Healthcare Team Outcomes

T-PLL is rare leukemia, and overall the prognosis is poor. T-PLL needs an interprofessional management approach with a medical oncologist, infectious disease physician, pharmacist, and oncology nurse, all working together as an interprofessional health team to bring about optimal clinical outcomes for the patient. [Level 5] The oncology nurse and pharmacist should educate the patient on the adverse effects of the chemotherapy drugs used to manage this leukemia to help drive the best possible patient outcomes.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Laribi K, Lemaire P, Sandrini J, Baugier de Materre A. Advances in the understanding and management of T-cell prolymphocytic leukemia. Oncotarget. 2017 Nov 28;8(61):104664-104686. [PMC free article: PMC5732835] [PubMed: 29262669]

2.

Kiel MJ, Velusamy T, Rolland D, Sahasrabuddhe AA, Chung F, Bailey NG, Schrader A, Li B, Li JZ, Ozel AB, Betz BL, Miranda RN, Medeiros LJ, Zhao L, Herling M, Lim MS, Elenitoba-Johnson KS. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood. 2014 Aug 28;124(9):1460-72. [PMC free article: PMC4148768] [PubMed: 24825865]

3.

Singhal M, Raina V, Gupta R, Das P. T cell-prolymphocytic leukemia detected in a patient of breast cancer at the time of recurrence: a case report. Cases J. 2010 Jan 04;3:4. [PMC free article: PMC2806858] [PubMed: 20076807]

4.

Kasinathan G, Kori AN, Azmie NM. Post-transplant lymphoproliferative disorder presenting as T-prolymphocytic leukemia: a case report. J Med Case Rep. 2019 Jul 22;13(1):223. [PMC free article: PMC6643311] [PubMed: 31327318]

5.

Jain P, Aoki E, Keating M, Wierda WG, O'Brien S, Gonzalez GN, Ferrajoli A, Jain N, Thompson PA, Jabbour E, Kanagal-Shamanna R, Pierce S, Alousi A, Hosing C, Khouri I, Estrov Z, Cortes J, Kantarjian H, Ravandi F, Kadia TM. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). Ann Oncol. 2017 Jul 01;28(7):1554-1559. [PMC free article: PMC5834082] [PubMed: 28379307]

6.

Matutes E, Brito-Babapulle V, Swansbury J, Ellis J, Morilla R, Dearden C, Sempere A, Catovsky D. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood. 1991 Dec 15;78(12):3269-74. [PubMed: 1742486]

7.

Collignon A, Wanquet A, Maitre E, Cornet E, Troussard X, Aurran-Schleinitz T. Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment. Curr Oncol Rep. 2017 Apr;19(4):29. [PubMed: 28324286]

8.

Garlisi CG, Mastro AM. Characterization of the inhibition of interleukin 2 mRNA accumulation by 12-O-tetradecanoylphorbol-13-acetate in primary lymphocytes. Lymphokine Cytokine Res. 1992 Feb;11(1):1-8. [PubMed: 1576243]

9.

Janot C, Feriel J, Borie C, Lefevre E, Bennaceur-Griscelli A, Turhan AG, Aumont C. Clinically silent indolent T-cell leukemia. Clin Case Rep. 2019 Jan;7(1):24-26. [PMC free article: PMC6332809] [PubMed: 30656001]

10.

Staber PB, Herling M, Bellido M, Jacobsen ED, Davids MS, Kadia TM, Shustov A, Tournilhac O, Bachy E, Zaja F, Porkka K, Hoermann G, Simonitsch-Klupp I, Haferlach C, Kubicek S, Mayerhoefer ME, Hopfinger G, Jaeger U, Dearden C. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood. 2019 Oct 03;134(14):1132-1143. [PMC free article: PMC7042666] [PubMed: 31292114]

11.

Colon Ramos A, Tarekegn K, Aujla A, Garcia de de Jesus K, Gupta S. T-Cell Prolymphocytic Leukemia: An Overview of Current and Future Approaches. Cureus. 2021 Feb 09;13(2):e13237. [PMC free article: PMC7948687] [PubMed: 33728186]

12.

Dearden CE, Matutes E, Cazin B, Tjønnfjord GE, Parreira A, Nomdedeu B, Leoni P, Clark FJ, Radia D, Rassam SM, Roques T, Ketterer N, Brito-Babapulle V, Dyer MJ, Catovsky D. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001 Sep 15;98(6):1721-6. [PubMed: 11535503]

13.

Keating MJ, Cazin B, Coutré S, Birhiray R, Kovacsovics T, Langer W, Leber B, Maughan T, Rai K, Tjønnfjord G, Bekradda M, Itzhaki M, Hérait P. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol. 2002 Jan 01;20(1):205-13. [PubMed: 11773171]

14.

Herbaux C, Kornauth C, Poulain S, Chong SJF, Collins MC, Valentin R, Hackett L, Tournilhac O, Lemonnier F, Dupuis J, Daniel A, Tomowiak C, Laribi K, Renaud L, Roos-Weil D, Rossi C, Van Den Neste E, Leyronnas C, Merabet F, Malfuson JV, Tiab M, Ysebaert L, Ng S, Morschhauser F, Staber PB, Davids MS. BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. Blood. 2021 Jun 24;137(25):3495-3506. [PubMed: 33598678]

15.

Dearden C. How I treat prolymphocytic leukemia. Blood. 2012 Jul 19;120(3):538-51. [PubMed: 22649104]

Disclosure: Hatem Kaseb declares no relevant financial relationships with ineligible companies.

Disclosure: Ankit Madan declares no relevant financial relationships with ineligible companies.

Disclosure: Robert Killeen declares no relevant financial relationships with ineligible companies.

Disclosure: Sameh Hozayen declares no relevant financial relationships with ineligible companies.